Current AD pharmacotherapy focuses mainly on the impairment of cholinergic and glutamatergic systems, the acetylcholinesterase (AChE) inhibitors donepezil [8], galantamine [9], rivastigmine [8] and memantine, a N-methyl-d-aspartate antagonist [8,10], being the only clinically administered drugs, albeit with limited therapeutic success. The gene discussed is ACHE; the disease is Alzheimer disease.